BioSpace News Archive

RaySearch Laboratories AB announces that McLaren Proton Therapy Center in Flint, Michigan, has placed an order for the treatment planning system RayStation®*.

Avantor, Inc. reported financial results for the quarter ended September 30, 2022.

Chemomab Therapeutics Ltd . today announced that the company will participate in several scientific conferences in November.

Numinus Wellness Inc. today announced the launch of its Ketamine for Chronic and Serious Medical Illness Program.

ZyVersa Therapeutics, Inc. are pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at BioFlorida’s 2022 Annual Conference being held in Miami, Florida on November 2-4, 2022.

NeoGenomics, Inc. is providing an update on its discussions with MolDX and on its commercial launch activities for RaDaR TM, its proprietary assay for the detection of minimal residual disease (MRD) and recurrence.

TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 54,600 shares of its common stock and restricted stock units covering 7,500 shares of its common stock to 11 newly-hired employees, with a grant date of October 26, 2022.

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the fourth quarter of 2022.

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”) today announced that it has voluntarily withdrawn its pending Biologics License Application (BLA) for leronlimab as a combination therapy in persons living with HIV with resistance to highly active antiretroviral therapy (HAART) in the HIV multi-drug resistant population (HIV-MDR).

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended August 31, 2022.